drugset / Trial / NCT06005324

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

NCT06005324

Phase 1 Recruiting 36 enrolled University of Chicago
Non-randomizedSequentialOpen-labelTreatment

Summary

This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.

Timeline

Start
2023-12-18
Primary completion
2026-06
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule
Subject Cetuximab Monoclonal antibody
Subject Cisplatin Other / unclassified
Subject Hydroxyurea Other / unclassified
Subject Paclitaxel Small molecule
Subject fluorouracil Small molecule